 |
TSO3 Refocuses its Marketing Activities to Accelerate Sales and Revenue GrowthJune 5, 2008Quebec City, Quebec, Canada, June 5, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces that it is realigning resources and re-focusing marketing activities to enhance its rate of market penetration and sales growth for 2008 and beyond. These initiatives will also allow the Company to significantly reduce its operating expenses rate thanks to more efficient use of sales and marketing resources.Initiatives impact four areas: (1) market segmentation of the primary North American hospital market, using a contracted specialized US marketing firm in conjunction with direct selling resources; (2) realign sales resources to more effectively focus its senior sales management team on targets in the pipeline and sales leads; (3) reducing cash burn rate for 2008 by $2.1 million; (4) assessing and prioritizing R&D projects with resource additions as needed. Additionally, TSO3 will be analysing other near term sales opportunities for its 125L Ozone Sterilizer by evaluating other territories or market sectors, such as other countries and medical device companies, which offer pre-sterilized products to the market. TSO3 is already seeing early indications of momentum from these recent initiatives with several target accounts pending purchase decisions. “These new measures should allow us to generate sales momentum to achieve our expected sales forecast, while attaining a net effect of cash burn rate reduction of $2.1M for the remainder of the year”, stated W. Barry McDonald, Interim CEO for TSO3. “This re-focusing and realigning is being done with the intent of maximising the very capable sales resources that we have on board at management level, to generate sales in the very short term and ensure business growth in 2008 and beyond”. TSO3 plans to give an update on the progress of these initiatives and provide further quantitative financial information on its reduced operating expenses, on or before its next quarterly release in early August. Moreover, from now on, the sales realized by the Company during the normal course of its operations will be disclosed within the quarterly results report. Conference call TSO3 will host a Conference Call at 11:00 A.M. (ET), on June 6, 2008. Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3415 (Toronto area) or the toll-free number 1 800 733-7560. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3’s Website at: www.tso3.com The Webcast will be archived for 90 days. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company’s Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Marc Boisjoli CFO (418) 651-0003, Ext. 228 mboisjoli@tso3.com Frédéric Tremblay HKDP Tel.: 514 395-0375, Ext. 234 |
© 2005-2008 TSO3. All Rights Reserved.
